Key Points
- CEO Leon Moulder Jr. purchased 30,000 shares on Jan. 8 at $16.30 for $489,000, increasing his stake to 346,155 shares (a 9.49% rise), and filings indicate roughly ~100,000 shares were bought across Jan. 7–9 (≈$1.63M aggregate), a strong insider-buy signal.
- Zenas reported a quarterly EPS of -$1.22 (missing the -$0.87 estimate), remains unprofitable with a negative P/E and ~$863M market cap, and faces a Pomerantz LLP investigation that could heighten near-term volatility.
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 20,000 shares of the firm's stock in a transaction on Friday, January 9th. The shares were acquired at an average price of $16.55 per share, for a total transaction of $331,000.00. Following the purchase, the chief executive officer directly owned 366,155 shares of the company's stock, valued at approximately $6,059,865.25. This represents a 5.78% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Zenas BioPharma Stock Performance
Zenas BioPharma stock opened at $16.08 on Friday. The stock has a fifty day moving average price of $34.94 and a two-hundred day moving average price of $24.01. The firm has a market capitalization of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma, Inc. has a 52-week low of $5.83 and a 52-week high of $44.60. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.35).
Key Zenas BioPharma News
Here are the key news stories impacting Zenas BioPharma this week:
- Positive Sentiment: CEO insider buying — Leon Moulder Jr. purchased roughly $1.63M of ZBIO stock across Jan. 7–9 (aggregate ≈ 100,000 shares), raising his stake to ~366,155 shares. Large, repeated insider purchases often signal management confidence and can support near‑term buying interest from investors. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
- Positive Sentiment: Brokerage sentiment is constructive — analysts’ consensus rating is "Moderate Buy," which can attract institutional or retail demand if reiterated publicly. This supports a bullish narrative alongside insider purchases. Zenas BioPharma Given Consensus Recommendation of "Moderate Buy"
- Neutral Sentiment: Regulatory transparency — multiple SEC filings disclose the CEO’s trades (dates, quantities, prices), confirming the transactions are official and recently reported; useful for verifying timing and cost basis. SEC filing confirming insider purchases
- Neutral Sentiment: Mixed analyst landscape — several firms maintain buy/outperform ratings while others are cautious and price targets vary widely; this leaves upside expectations dispersed among investors. MarketBeat ZBIO analyst summary
- Negative Sentiment: Pomerantz LLP announced an investor alert investigating Zenas BioPharma, creating potential litigation risk and short‑term volatility — such probes can prompt selling pressure until scope and substance are clarified. Pomerantz investigates Zenas BioPharma
Hedge Funds Weigh In On Zenas BioPharma
Institutional investors have recently added to or reduced their stakes in the stock. Quarry LP raised its stake in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company's stock valued at $25,000 after buying an additional 291 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Zenas BioPharma in the third quarter worth about $30,000. BNP Paribas Financial Markets raised its position in shares of Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company's stock valued at $70,000 after purchasing an additional 1,716 shares during the period. PNC Financial Services Group Inc. grew its stake in Zenas BioPharma by 41.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in Zenas BioPharma in the 2nd quarter valued at approximately $118,000.
Analyst Ratings Changes
A number of brokerages recently commented on ZBIO. Evercore ISI started coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They issued an "outperform" rating and a $55.00 target price for the company. Jefferies Financial Group reissued a "buy" rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday. Citigroup upped their target price on Zenas BioPharma from $27.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, October 28th. HC Wainwright restated a "buy" rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Finally, Morgan Stanley downgraded shares of Zenas BioPharma from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $37.00 to $19.00 in a report on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Zenas BioPharma currently has a consensus rating of "Moderate Buy" and an average price target of $43.14.
Check Out Our Latest Research Report on ZBIO
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
